BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1777 related articles for article (PubMed ID: 27160722)

  • 1. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. <Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
    Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
    Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dual Role of Treg in Cancer.
    Frydrychowicz M; Boruczkowski M; Kolecka-Bednarczyk A; Dworacki G
    Scand J Immunol; 2017 Dec; 86(6):436-443. PubMed ID: 28941312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Treg cells in cancer immunotherapy.
    Tanaka A; Sakaguchi S
    Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells.
    Beauford SS; Kumari A; Garnett-Benson C
    BMC Immunol; 2020 Apr; 21(1):18. PubMed ID: 32299365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells in tumor immunity.
    Nishikawa H; Sakaguchi S
    Int J Cancer; 2010 Aug; 127(4):759-67. PubMed ID: 20518016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe AE; Vignali DAA
    Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses towards regulatory cells.
    Larsen SK
    Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
    D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance.
    Hibino S; Chikuma S; Kondo T; Ito M; Nakatsukasa H; Omata-Mise S; Yoshimura A
    Cancer Res; 2018 Jun; 78(11):3027-3040. PubMed ID: 29559474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
    Togashi Y; Shitara K; Nishikawa H
    Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.